Bibliographic information
GuidelineTherapeutics and COVID-19: living guideline, August 2025
Year of Publication2025
Issuing InstitutionWorld Health Organization
Recommendation
New
We recommend not to use SGLT-2 inhibitors for severe or critical COVID-19 . This recommendation does not apply to individuals already receiving an SGLT-2 inhibitor for an alternate indication.
Recommended against
Strong
Notes and Remarks
Practical info The GDG made a strong recommendation against using SGLT-2 inhibitors for treatment of patients with severe or critical COVID-19 and therefore practical considerations are not relevant for this drug.